FDA approves a new ADHD drug. It still needs the DEA's sign-off before anyone can buy it

The FDA approved Simtriyo (centanafadine) on 24 July for the treatment of ADHD in adults and children aged 6 and older weighing at least 20 kilograms, according to Otsuka Pharmaceutical, the drug's manufacturer, and FDA's own novel drug approvals log for the year [s1, s2]. It is the first drug in a new mechanistic class — a norepinephrine, dopamine and serotonin reuptake inhibitor, or NDSRI [s1].

It will not reach pharmacies immediately. Otsuka's own announcement states that Simtriyo "is expected to be available later this year following scheduling by the U.S. Drug Enforcement Administration (DEA)" [s1]. The company's press release describes the drug plainly, in its own language, as "an NDSRI and central nervous system (CNS) stimulant" [s1] — a classification that puts it under the DEA's controlled-substance framework regardless of how it is marketed or discussed clinically.

What makes the mechanism different

Existing ADHD medications generally fall into two categories: stimulants, which are Schedule II controlled substances acting primarily on dopamine and norepinephrine, and non-stimulants such as atomoxetine, which typically act on norepinephrine alone and are not scheduled. Centanafadine's mechanism — inhibiting reuptake of norepinephrine, dopamine, and additionally serotonin — does not map cleanly onto either established category [s1]. That third target, serotonin, is the basis for treating it as mechanistically novel rather than as a reformulation of an existing drug class.

Coverage of the approval has frequently described Simtriyo using the shorthand "non-stimulant," a label that tracks the drug's difference from Schedule II amphetamine- and methylphenidate-based medications but does not track how FDA and the manufacturer are actually classifying and regulating it. The company's own materials call it a stimulant. That distinction is not a technicality: it is the reason the drug needs a DEA scheduling determination before it can be sold, a step non-scheduled non-stimulant medications do not require.

What supported the approval

Otsuka says the approval rests on four pivotal Phase 3 randomized, double-blind, placebo-controlled trials spanning children, adolescents and adults [s1]. In the two pivotal adult trials, both tested centanafadine dose groups produced statistically significant improvements on the Adult ADHD Investigator Symptom Rating Scale compared with placebo, with improvements observed as early as week 1 and maintained through six weeks of treatment [s1]. Pediatric and adolescent trials used the ADHD Rating Scale-5 and showed a similar pattern of early, sustained separation from placebo [s1].

The most commonly reported adverse events differed somewhat by age group: decreased appetite, nausea, rash, headache and abdominal pain in children and adolescents; headache, decreased appetite, insomnia, nausea, dry mouth and diarrhea in adults [s1]. Otsuka's chief medical officer, John Kraus, called the approval "an important milestone for people living with ADHD," noting the disorder's highly individualized presentation across a patient's life [s1]. Lenard Adler, director of the adult ADHD program at NYU Langone Health, said the approval "introduces a novel mechanism of action and expands the range of options available to healthcare professionals and patients," while noting many patients on existing treatment continue to experience symptoms that interfere with daily functioning [s1].

Why the DEA step is not a formality

Scheduling decisions are not automatic once a drug is approved. The DEA independently evaluates a substance's abuse potential, dependence liability and actual pattern of use before assigning it to a schedule, a process that runs on its own timeline separate from FDA's approval. For a drug FDA has approved and its own manufacturer has already characterized as a CNS stimulant, that process is a predictable next step rather than a surprising one — but it is also a real gate. Centanafadine cannot be legally dispensed until the DEA completes it, meaning approval and market availability are, for this drug, two distinct milestones on two different regulatory clocks.

Otsuka's own timeline projection — availability "later this year" — is the company's estimate, not a DEA commitment, and scheduling reviews have historically taken anywhere from a few months to considerably longer depending on the substance and the completeness of the abuse-liability data package submitted.

What to watch

How quickly the DEA completes scheduling, and which schedule it assigns — a decision that will determine prescribing restrictions, refill rules and how pharmacies handle the drug once it does reach the market. Otsuka has also flagged a completed Phase 3b study in adults with ADHD and comorbid anxiety showing statistically significant symptom improvement, with full results still pending presentation at a future scientific meeting [s1] — a data set that could expand the drug's evidence base beyond the initial approval population. This article describes regulatory and clinical trial information; it is not a treatment recommendation, and questions about ADHD management belong with a treating clinician.

Sources

• [s1] Otsuka Pharmaceutical, "Otsuka Receives FDA Approval for First-in-Class SIMTRIYO (centanafadine) for the Treatment of Attention-Deficit Hyperactivity Disorder (ADHD) in Adults and Pediatric Patients Aged 6 Years and Older," press release, 24 July 2026. https://www.otsuka-us.com/otsuka-shares-fda-review-update-for-centanafadine
• [s2] U.S. Food and Drug Administration, "Novel Drug Approvals for 2026," accessed 24 July 2026. https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2026